Skip to main content
Clinical Trials/NCT04689464
NCT04689464
Completed
N/A

COVID19 and Psychological Health: a Cross Sectional Evaluation of the Risks of Anxiety and Depression Among Patients Diagnosed With Covid 19

Alhasan Mujtaba Al-Mudhaffer1 site in 1 country450 target enrollmentDecember 1, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Covid19
Sponsor
Alhasan Mujtaba Al-Mudhaffer
Enrollment
450
Locations
1
Primary Endpoint
depression
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The covid-19 pandemic started to spread worldwide since December 2019. It promoted to an exaggerated psychological stress and anxiety in humans due to the intolerable symptoms higher than usual death of many infected patients. This study examines the corona related anxiety and if there is need for drug intervention to treat this anxiety.

To answer these questions, a survey made to the hospitalized patients including sex, age, educational level, Marital state, and a standardized questionnaires (GAD-7 and PHQ-9) which has been validated and shown to possess good psychometric qualities in studies of participants from multiple populations.

Registry
clinicaltrials.gov
Start Date
December 1, 2020
End Date
June 1, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Alhasan Mujtaba Al-Mudhaffer
Responsible Party
Sponsor Investigator
Principal Investigator

Alhasan Mujtaba Al-Mudhaffer

Clinical Pharmacy Specialist

AlFayhaa General Hospital

Eligibility Criteria

Inclusion Criteria

  • patients with COVID19 willing to participate in the study

Exclusion Criteria

  • unwilling unable to read or interact with standardized questionnaire unconscious

Outcomes

Primary Outcomes

depression

Time Frame: at the time of acute infection, average of 1 month

Depression measured by Patient Health Questionnaire-9 (PHQ-9) scale. Scoring: 5-9 mild;10-14 moderate; 15-19 moderately severe; \>20 severe. Minimum 0 maximum 27 points

anxiety

Time Frame: at the time of acute infection, average of 1 month

Anxiety measured by General Anxiety Disorder-7 (GAD-7) scale. Scoring:5-9 mild; 10-14 moderate; \>15 severe. Minimum 0, maximum 21 points

Study Sites (1)

Loading locations...

Similar Trials